NCT07703436
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07703436
Title Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Nuvation Bio Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of California, Los Angeles Los Angeles California 90095 United States Details
University of California, San Francisco San Francisco California 94143 United States Details
Rutgers Cancer Institute New Brunswick New Jersey 08901 United States Details
NYU Langone Health New York New York 10016 United States Details
University of Rochester Medical Center Rochester New York 14642 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field